Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ: RXRX )

6.030 -0.060 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
From FN Media Group LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Operational complementarities expected to yield annual synergies of approximately $100 million 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Proposed Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur 
From Recursion Pharmaceuticals
Via GlobeNewswire
The Next Drug You Take May be Designed By A.I.
Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. 
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.